BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694

  Zenith Capital Corp. announces the publication of an important study which has uncovered the role of ZEN-3694.

  June 24, 2021

   · 

  4 min read
• Drug Development

  Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer’s Association International Conference

  Longeveron Inc. announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patients with mild Alzheimer’s disease has been accepted for a Developing Topics poster presentation at the 2021 Annual Alzheimer’s Association International Conference.

  June 24, 2021

   · 

  4 min read
• Drug Development

  Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer

  Sirnaomics, Inc. announced today dose administration for the first patient in a Phase 1 U.S. clinical study for liver cancer treatment.

  June 24, 2021

   · 

  6 min read
• Biotech Beach

  HUYABIO Announces HBI-8000 Brand Name of Hiyasta™

  HUYABIO International announced today that HBI-8000 will be marketed under the brand name Hiyasta ™ in Japan .

  June 24, 2021

   · 

  2 min read
• Drug Development

  Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration

  Alpine Immune Sciences, Inc. announced today that the first patient has been dosed in Synergy, a Phase 2 study of ALPN-101 in patients with Systemic Lupus Erythematosus (SLE).

  June 24, 2021

   · 

  5 min read
• Business

  Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

  Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005;

  June 24, 2021

   · 

  7 min read
• Drug Development

  Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

  Aeglea BioTherapeutics, Inc. today announced the dosing of the first patient in the Company’s first-in-human Phase 1/2 clinical trial investigating AGLE-177 for the treatment of Homocystinuria.

  June 24, 2021

   · 

  6 min read
• Business

  Merck Appoints Michael Klobuchar Chief Strategy Officer

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael Klobuchar has been appointed executive vice president and chief strategy officer, a newly created role, effective July 5, 2021.

  June 24, 2021

   · 

  4 min read
• Business

  Accelerator Life Science Partners Expands Executive Team with Appointment of Alice Chen as Executive Vice President

  Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that it has strengthened its executive leadership team with the promotion of Alice Chen, Ph.D., to executive vice president and the addition of Ronald Howell as Senior Advisor.

  June 24, 2021

   · 

  4 min read
• Implantable Sensor Market Growing Adoption of Mobile Healthcare Technologies

  The report highlights trends prevailing in the global implantable sensor market, and the factors driving and restraining the market growth.

  June 24, 2021

   · 

  5 min read